• Most Popular
  • Most Shared

Health Videos

Leeches therapy industry booms

As leech therapy gains popularity, a laboratory near Moscow is boosting production of this increasingly valuable -- and slimy -- commodity.  Video 

Under the knife, without the knife

Autopsies have gone virtual thanks to Swiss forensic pathologists who are conducting about 100 ''virtopsies'' a year.  Video 

Biotech drug costs up 8.7 percent: survey

LONDON
Fri Sep 26, 2008 8:31am EDT

LONDON (Reuters) - The cost of specialty biotech drugs increased 8.7 percent last year in the United States, three times the rate of inflation, according to AARP, a Washington-based group representing the elderly.

Health

Such drugs -- from companies including Amgen, Genentech, Pfizer and Johnson & Johnson -- are used to treat complex illnesses including cancer and rheumatoid arthritis and are among the most expensive drugs on the market.

Prices range from $5,000 to more than $300,000 a year.

"The skyrocketing cost of specialty drugs is especially tragic for those suffering from diseases like cancer and multiple sclerosis," John Rother, AARP executive vice president of policy and strategy, said in a statement on the group's website here

"These drugs can provide comfort and hope to these individuals and their families. But even the most miraculous drug is useless if people can't afford to take it."

On average in the four-year period from 2003 to 2007, prices for 112 popular specialty drugs increased by 42.9 percent, compared to the general inflation rate of 14.1 percent, the report said.

(Reporting by Ben Hirschler; Editing by Quentin Bryar)



More from Reuters

Photo

Plot exposes fissure in U.S. intelligence community

WASHINGTON (Reuters) - Last week's failed plot to bomb a U.S. passenger jet has exposed lingering fissures within the U.S. intelligence community, which had information from interviews and clandestine intercepts but did not put the pieces together, officials said.

Floor traders work at the Hong Kong Stocks Exchange, January 16, 2008.   REUTERS/Bobby Yip

My way or the highway?

Hong Kong is poised to accept Beijing's accounting standards. That's good. The system, though, is prone to scandal. That's bad.  Full Article 

People walk past a branch of Bank of America in New York's financial district April 28, 2009. REUTERS/Brendan McDermid

Move your money

Boycotting "too big to fail" banks is a great idea -- so long as investors remember that banks aren't the only ones responsible for the crisis.  Full Article